REN and heart failure: The PARADIGM-HF trial, conducted in 8442 patients with heart failure, confirmed that neprilysin inhibition (when added to renin-angiotensin system blockade) reduces hospitalization and death due to heart failure but probably has little effect on the risk of stroke or myocardial infarction [61].